Tag: Eli Lilly and Co
-
J&J’s 6% slide on an imperfect quarter is a gift to prospective buyers
J&J’s pharmaceutical division is humming along, and the MedTech problems should be temporary.
-
Walmart to cover some GLP-1s, inhalers and insulin for employees at no cost as it expands benefits
Walmart will offer Novo’s Ozempic and Lilly’s Mounjaro without charge for people with Type 2 diabetes after a new prior authorization.
-
Biogen is set for big gains on slate of trial data releases, JPMorgan says
Biogen will release data from clinical trials for a few of its investigational treatments over the next few months, which should boost its shares, per JPMorgan.
-
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
-
There’s one pharma-linked stock most investors have never heard of. It’s on Josh Brown’s list
If you’ve ever gotten a vaccine, this company was likely part of how that drug reached you, says Josh Brown.
-
Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
Lilly said it plans to start Phase 3 trials on the combo regimen adding its amylin drug eloralintide to tirzepatide at the end of the year.
-
People switching to Novo’s Wegovy pill from obesity injections kept losing weight in real-world study
The data on Novo’s Wegovy pill suggests that patients may not need to take weekly injections forever, but can instead opt for more convenient treatments.
-
Here are the 4 big things we’re watching in the stock market in the week ahead
Both sides of the Fed’s dual mandate are in focus. Plus, Micron reports and Eli Lilly delivers updates on its obesity pipeline.
-
Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.
-
Pharma stock soars 150% on injectables deal with Wegovy maker Novo
Shares in Swedish microcap stock Nanexa more than doubled after the drug-delivery group revealed a licensing deal with European pharma giant Novo Nordisk.
Latest News
Stay Connected
Categories
BBC News CNA CNBC CNN International Deutsche Welle (DW) Euronews France 24 General Global & European Specialized & Regional
Tags
amp Artificial intelligence Asia Breaking News: Business Breaking News: Markets Breaking News: Politics Breaking News: Technology Business business news cent china cup Donald J. Trump Donald Trump economy European Union fast football France germany india Investment strategy iran Iran war markets People per politics return russia S&P 500 Index said Singapore spain Sport Stock markets technology trump ukraine United States US-Israel attack on Iran 2026 video War in Ukraine World World Cup 2026
About the Author
AF themes
Easy WordPress Websites Builder: Versatile Demos for Blogs, News, eCommerce and More – One-Click Import, No Coding! 1000+ Ready-made Templates for Stunning Newspaper, Magazine, Blog, and Publishing Websites.
Search the Archives
Access over the years of investigative journalism and breaking reports
You May Have Missed
